Biogen Reports Mixed Phase 2 Data For Its Non-Opioid Pain Candidate

Biogen Inc BIIB has announced topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074) for small fiber neuropathy (SFN).
SFN is a disorder in which only the small sensory cutaneous nerves are affected and is often characterized by severe pain that typically begins in the feet or hands.
Vixotrigine is a non-opioid investigational oral pain drug.
The CONVEY study 200 mg twice daily arm met its primary endpoint of change from baseline to week 12 in mean average daily pain (ADP) score.
Numeric advantage of 200 mg over placebo was observed in additional secondary endpoints, including the proportion of participants with at least 2-point improvement in the average daily pain score and the proportion of participants with over 30% reduction in ADP at week 12, but these did not meet statistical significance.
While the 350 mg twice daily arm did not meet the primary endpoint, it met statistical significance in the Patient Global Impression of Change (PGIC) at week 12, a self-reported measure of a patient's overall improvement.
The totality of data from the vixotrigine program will inform potential doses for study in future Phase 3 clinical trials.
Both doses of vixotrigine were generally well tolerated.
Vixotrigine (BIIB074) is an investigational peripherally and centrally acting, orally-administered, voltage- and use-dependent voltage-gated sodium channel blocker.
UBS analyst Colin Bristow maintains Biogen with a Buy and lowers the price target from $475 to $442.
Price Action: BIIB stock is up 0.60% at $301.02 during the market session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga